title: Pretreatment platelet reactivity contribution to residual, post-treatment platelet reactivity in prasugrel-treated and ticagrelor-treated patients.
authors.forename: D
authors.initials: D
authors.lastname: Alexopoulos
authors.forename: I
authors.initials: I
authors.lastname: Xanthopoulou
authors.forename: P
authors.initials: P
authors.lastname: Davlouros
authors.forename: G
authors.initials: G
authors.lastname: Tsigkas
authors.forename: A
authors.initials: A
authors.lastname: Damelou
authors.forename: K C
authors.initials: KC
authors.lastname: Theodoropoulos
authors.forename: V
authors.initials: V
authors.lastname: Gkizas
authors.forename: G
authors.initials: G
authors.lastname: Hahalis
mesh_terms: D000241:Adenosine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000244:Adenosine Diphosphate; D001792:Blood Platelets / Q000187:drug effects* / Q000378:metabolism; D006801:Humans; D009203:Myocardial Infarction / Q000097:blood / Q000188:drug therapy / Q000628:therapy*; D062645:Percutaneous Coronary Intervention / Q000009:adverse effects; D010879:Piperazines / Q000627:therapeutic use*; D010974:Platelet Aggregation / Q000187:drug effects; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D010979:Platelet Function Tests; D000068799:Prasugrel Hydrochloride; D011237:Predictive Value of Tests; D058921:Purinergic P2Y Receptor Antagonists / Q000627:therapeutic use*; D058925:Receptors, Purinergic P2Y12 / Q000097:blood / Q000187:drug effects; D013876:Thiophenes / Q000627:therapeutic use*; D000077486:Ticagrelor; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: C548576:P2RY12 protein, human; D010879:Piperazines; D010975:Platelet Aggregation Inhibitors; D058921:Purinergic P2Y Receptor Antagonists; D058925:Receptors, Purinergic P2Y12; D013876:Thiophenes; D000244:Adenosine Diphosphate; D000068799:Prasugrel Hydrochloride; D000077486:Ticagrelor; D000241:Adenosine